Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
March 14 2023 - 4:30PM
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage biotechnology company specializing in the
development of AI-powered immunotherapies, today announced that the
company will present clinical readout of the Phase 1/2a trial of
EVX-02 at the upcoming 2023 American Association for Cancer
Research Annual Meeting (2023 AACR), taking place from April 14th
to April 19th in Orlando, Florida.
Pér Norlen, CEO at Evaxion, said: “Our unique
AI platform PIONEER has allowed the development of personalized
cancer immunotherapies that have the potential to improve the
treatment of melanoma as well as of other cancers. We look forward
to sharing the clinical phase 1/2a data of our personalized DNA
vaccine EVX-02 with the oncology community during the 2023 AACR
meeting.”
Title: A personalized neoantigen vaccine is well
tolerated and induces specific T-cell immune response in patients
with resected melanomaAbstract #:
23-LB-9549-AACRSession: Immune response to
therapiesLocation: Poster section
35Time: Tuesday, April 18, 2023 9:00 AM - 12:30
PM
About EvaxionEvaxion Biotech A/S is a
clinical-stage biotech company developing AI-powered
immunotherapies. Evaxion’s proprietary and scalable AI technologies
decode the human immune system to discover and develop novel
immunotherapies for cancer, bacterial diseases, and viral
infections. Evaxion has a broad pipeline of product candidates,
including three personalized cancer immunotherapies. It is located
in Hørsholm, Denmark, with 70 employees and is listed on the Nasdaq
New York stock exchange. For more information, please
visit: www.evaxion-biotech.com.
For more informationPer Norlén,
CEO Evaxion Biotech A/S
via:Katrine Hertz MortensenVP, Communications and Public
Relationskhm@evaxion-biotech.com+45 3010 0203
Forward-looking statementThis announcement
contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. The
words “target,” “believe,” “expect,” “hope,” “aim,” “intend,”
“may,” “might,” “anticipate,” “contemplate,” “continue,”
“estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can
have,” “likely,” “should,” “would,” “could,” and other words and
terms of similar meaning identify forward-looking
statements. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
factors, including, but not limited to, risks related to: our
financial condition and need for additional capital; our
development work; cost and success of our product development
activities and preclinical and clinical trials; commercializing any
approved pharmaceutical product developed using our AI platform
technology, including the rate and degree of market acceptance of
our product candidates; our dependence on third parties including
for conduct of clinical testing and product manufacture; our
inability to enter into partnerships; government regulation;
protection of our intellectual property rights; employee matters
and managing growth; our ADSs and ordinary shares, the impact
of international economic, political, legal, compliance, social and
business factors, including inflation, and the effects on
our business from the worldwide COVID-19 pandemic and the
ongoing conflict in the region
surrounding Ukraine and Russia; and other
uncertainties affecting our business operations and financial
condition. For a further discussion of these risks, please
refer to the risk factors included in our most recent Annual Report
on Form 20-F and other filings with the U.S. Securities
and Exchange Commission (SEC), which are available
at www.sec.gov. We do not assume any
obligation to update any forward-looking statements except as
required by law.
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jul 2023 to Jul 2024